Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Eye Drops for Persistent Corneal Epithelial Defect
2024-518818-53-00Phase 3Authorised
- Sponsor
- Hospital Clínico San Carlos
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of human insulin in corneal persistent epithelial defect (PED) (2 arms), sponsored by Hospital Clínico San Carlos. Primary endpoints: Complete re-epithelialisation rate, Closure rate and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
human insulin
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on 2024-518818-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518818-53-00.